Cancer News and Research

Latest Cancer News and Research

Provenge cellular immunotherapy for men with advanced prostate cancer receives FDA approval

The U.S. Food and Drug Administration today approved Provenge (sipuleucel-T), a new therapy for certain men with advanced prostate cancer that uses their own immune system to fight the disease.

30 Apr 2010

Study promises a new treatment for cancer

Cancer cells producing toxins that destroy tumours - could this be a future treatment for cancer? Researchers at Lund University have achieved good results in tests on both cells and animals.

30 Apr 2010

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that it has entered into an exclusive US $75 million license agreement with Kissei Pharmaceutical Co., Ltd. for the development and commercialization of its PSA-activated pro-drug, PRX302, in Japan for BPH, prostate cancer and other diseases of the prostate. Protox retains exclusive rights to PRX302 in all other territories.

30 Apr 2010

Researchers identify key protein that regulates innate immune system

A team of researchers led by Baylor College of Medicine has identified a protein called NLRC5, a member of the NOD-like protein family, that is involved in inhibition of protein complexes key to critical pathways of innate immunity called NF-κB and type I interferon signaling. A report on their work appears in the current issue of the journal Cell.

30 Apr 2010

CRH Medical reports 115% increase in first-quarter 2010 revenue

CRH Medical Corporation announced today unaudited results for the three months ended March 31, 2010. Total revenue for the three months ended March 31, 2010 was $1,951,590 compared to $1,739,470 for the same period in 2009.

30 Apr 2010

Canadian researchers identify new therapeutic target for lung cancer

Lung cancer patients whose tumors over-express a cell surface molecule called CXCR4 do significantly worse than those who do not, Canadian researchers have found. Their work, reported at the 2nd European Lung Cancer Conference in Geneva, highlights the exciting possibility that the molecule could soon become a new target for personalized cancer therapy.

30 Apr 2010

EndoChoice granted FDA marketing clearance for BONASTENT Esophageal and Biliary Stent platforms

EndoChoice, Inc. today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) to market its BONASTENT® Fully Covered Esophageal Stent for the treatment of malignant esophageal obstructions, and its BONASTENT Uncovered Biliary Stent for the treatment of malignant biliary obstructions.

30 Apr 2010

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

Bristol-Myers Squibb Company today reported strong sales and earnings growth for the first quarter of 2010.

30 Apr 2010

FDA approves Provenge prostate cancer vaccine

Cancer may now be fought with a vaccine. The FDA has finally approved an immune boosting vaccine which is said to extend survival of patients at an advanced stage of prostate cancer by four months. This is twice as long as what could be expected with regular chemotherapy. There is also an increase of three years survival after detection in initial stage by 38% thanks to the vaccine.

30 Apr 2010

BioTime to acquire Singapore-based company, ES Cell International

BioTime, Inc., a biotechnology company that develops and markets products in the field of stem cells and regenerative medicine, today announced that it has agreed to acquire the Singapore-based company ES Cell International Pte Ltd.

30 Apr 2010

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

IRIS International, Inc., a leading manufacturer of automated in-vitro diagnostics systems and consumables for use in hospitals and commercial laboratories worldwide, announced today that its IRIS Molecular Diagnostics (IMD) subsidiary has submitted a 510(k) pre-market notification application to the U.S. Food and Drug Administration (FDA) requesting regulatory clearance for NADiA®ProsVue™, a prostate cancer prognostic test. The test is designed to help physicians identify patients at low risk of cancer recurrence post radical prostatectomy.

29 Apr 2010

FDA grants Bavarian Nordic Fast Track designation for PROSTVAC

Bavarian Nordic A/S announced today that PROSTVAC™ has been granted Fast Track designation by the U.S. Food & Drug Administration (FDA) for its proposed use in the treatment of men with asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC).

29 Apr 2010

NeoGenomics first-quarter revenue up 22%

NeoGenomics, Inc., a leading provider of cancer-focused genetic testing services today reported its results for the first quarter 2010.

29 Apr 2010

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Celgene Corporation announced non-GAAP net income of $294.6 million, or non-GAAP diluted earnings per share of $0.63 for the quarter ended March 31, 2010. Non-GAAP net income for the first quarter of 2009 was $205.1 million or non-GAAP diluted earnings per share of $0.44. Based on U.S. GAAP, Celgene reported net income of $234.4 million, or diluted earnings per share of $0.50 for the quarter ended March 31, 2010. GAAP net income for the first quarter of 2009 was $162.9 million, or diluted earnings per share of $0.35.

29 Apr 2010

Caliper Life Sciences' first-quarter 2010 GAAP revenues increase 1% to $28.7M

Caliper Life Sciences, Inc., today reported its first quarter 2010 results.

29 Apr 2010

Provectus reports on end-of-Phase 2 meeting with FDA on licensure of PV-10 for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announced today that it has held an end-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to seek consensus on clinical program scope and endpoints for licensure of PV-10 for metastatic melanoma. The meeting was held at the Agency's White Oak Campus in Silver Spring, MD.

29 Apr 2010

Study investigates efficacy of acellular dermal matrix for intestinal elongation

Acellular dermal matrix (ADM) is a dermal biomaterial in which all of the cellular elements have been removed. The biologic properties of ADM, including its ability to support tissue regeneration repopulation with fibroblasts, revascularization, new collagen deposition and eventual absorption and replacement with native tissue permit its use in tissue reconstruction.

29 Apr 2010

The OCD Project challenges six severe OCD sufferers to face fears in a bold move to better their lives

Obsessive-Compulsive Disorder is a disorder of the brain where people experience obsessive thoughts, images, ideas or impulses – and they can't get past them. The day-to-day existence for severe OCD sufferers is dire. Untreated, they lead lives of self-punishment, fear and isolation that can result in job loss, broken families, bankruptcy and in some cases death.

29 Apr 2010

Jiangsu Yanshen receives SFDA disciplinary notice for substandard quality human use rabies vaccine

Simcere Pharmaceutical Group, a leading pharmaceutical company specializing in the development, manufacturing, and marketing of branded generic and proprietary pharmaceuticals in China, today announced that Jiangsu Yanshen Biological Technology Stock Co., Ltd. has received disciplinary notice from China's State Food and Drug Administration regarding its production of substandard quality human use rabies vaccine.

29 Apr 2010

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

Human Genome Sciences, Inc. today announced financial results for the quarter ended March 31, 2010, and provided highlights of recent key developments.

29 Apr 2010

Cancer News and Research

Latest Cancer News and Research

Provenge cellular immunotherapy for men with advanced prostate cancer receives FDA approval

Study promises a new treatment for cancer

Kissei to commercialize Protox's PRX302 PSA-activated pro-drug for BPH, prostate cancer in Japan

Researchers identify key protein that regulates innate immune system

CRH Medical reports 115% increase in first-quarter 2010 revenue

Canadian researchers identify new therapeutic target for lung cancer

EndoChoice granted FDA marketing clearance for BONASTENT Esophageal and Biliary Stent platforms

Bristol-Myers Squibb reports 11% increase in first-quarter 2010 revenue

FDA approves Provenge prostate cancer vaccine

BioTime to acquire Singapore-based company, ES Cell International

IMD seeks FDA regulatory clearance for NADiA ProsVue prostate cancer prognostic test

FDA grants Bavarian Nordic Fast Track designation for PROSTVAC

NeoGenomics first-quarter revenue up 22%

Celgene's first-quarter non-GAAP total revenue up 31% to $789 million

Caliper Life Sciences' first-quarter 2010 GAAP revenues increase 1% to $28.7M

Provectus reports on end-of-Phase 2 meeting with FDA on licensure of PV-10 for metastatic melanoma

Study investigates efficacy of acellular dermal matrix for intestinal elongation

The OCD Project challenges six severe OCD sufferers to face fears in a bold move to better their lives

Jiangsu Yanshen receives SFDA disciplinary notice for substandard quality human use rabies vaccine

Human Genome Sciences reports net loss of $47.9M for first-quarter 2010

Understanding the DNA Damage Response in Innate Immunity eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Cancer News and Research

Latest Cancer News and Research

Understanding the DNA Damage Response in Innate Immunity eBook

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Newsletters you may be interested in